238 related articles for article (PubMed ID: 28178675)
1. Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.
Tsukagoshi M; Araki K; Yokobori T; Altan B; Suzuki H; Kubo N; Watanabe A; Ishii N; Hosouchi Y; Nishiyama M; Shirabe K; Kuwano H
Oncotarget; 2017 Jun; 8(26):42159-42172. PubMed ID: 28178675
[TBL] [Abstract][Full Text] [Related]
2. Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer.
Zhang Y; Zhang M; Yu F; Lu S; Sun H; Tang H; Peng Z
J Exp Clin Cancer Res; 2015 Dec; 34():145. PubMed ID: 26626145
[TBL] [Abstract][Full Text] [Related]
3. Nuclear karyopherin-α2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer.
Altan B; Yokobori T; Mochiki E; Ohno T; Ogata K; Ogawa A; Yanai M; Kobayashi T; Luvsandagva B; Asao T; Kuwano H
Carcinogenesis; 2013 Oct; 34(10):2314-21. PubMed ID: 23749771
[TBL] [Abstract][Full Text] [Related]
4. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.
Chen MH; Weng JJ; Cheng CT; Wu RC; Huang SC; Wu CE; Chung YH; Liu CY; Chang MH; Chen MH; Chiang KC; Yeh TS; Su Y; Yeh CN
Clin Cancer Res; 2016 Aug; 22(16):4225-35. PubMed ID: 27076629
[TBL] [Abstract][Full Text] [Related]
5. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
Sohal DP; Mykulowycz K; Uehara T; Teitelbaum UR; Damjanov N; Giantonio BJ; Carberry M; Wissel P; Jacobs-Small M; O'Dwyer PJ; Sepulveda A; Sun W
Ann Oncol; 2013 Dec; 24(12):3061-5. PubMed ID: 24146220
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
[TBL] [Abstract][Full Text] [Related]
8. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.
Shen DY; Zhan YH; Wang QM; Rui G; Zhang ZM
Liver Int; 2013 Jan; 33(1):137-48. PubMed ID: 23121546
[TBL] [Abstract][Full Text] [Related]
10. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.
Gluz O; Wild P; Meiler R; Diallo-Danebrock R; Ting E; Mohrmann S; Schuett G; Dahl E; Fuchs T; Herr A; Gaumann A; Frick M; Poremba C; Nitz UA; Hartmann A
Int J Cancer; 2008 Sep; 123(6):1433-8. PubMed ID: 18561322
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
[TBL] [Abstract][Full Text] [Related]
12. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of long non‑coding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma.
Bai JG; Tang RF; Shang JF; Qi S; Yu GD; Sun C
Mol Med Rep; 2018 Apr; 17(4):5328-5335. PubMed ID: 29393466
[TBL] [Abstract][Full Text] [Related]
14. KPNA2 is a promising biomarker candidate for esophageal squamous cell carcinoma and correlates with cell proliferation.
Ma S; Zhao X
Oncol Rep; 2014 Oct; 32(4):1631-7. PubMed ID: 25109899
[TBL] [Abstract][Full Text] [Related]
15. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study.
Bi C; Liu M; Rong W; Wu F; Zhang Y; Lin S; Liu Y; Wu J; Wang L
BMC Cancer; 2019 Mar; 19(1):213. PubMed ID: 30849962
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of KPNA2 inhibits autophagy in oral squamous cell carcinoma cell lines by blocking p53 nuclear translocation.
Lin F; Gao L; Su Z; Cao X; Zhan Y; Li Y; Zhang B
Oncol Rep; 2018 Jul; 40(1):179-194. PubMed ID: 29781035
[TBL] [Abstract][Full Text] [Related]
17. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
[TBL] [Abstract][Full Text] [Related]
18. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
Kobayashi H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Ann Surg; 2012 Aug; 256(2):288-96. PubMed ID: 22580938
[TBL] [Abstract][Full Text] [Related]
19. Importin KPNA2 is required for proper nuclear localization and multiple functions of NBS1.
Tseng SF; Chang CY; Wu KJ; Teng SC
J Biol Chem; 2005 Nov; 280(47):39594-600. PubMed ID: 16188882
[TBL] [Abstract][Full Text] [Related]
20. Pleomorphic adenoma gene 1 mediates the role of karyopherin alpha 2 and has prognostic significance in hepatocellular carcinoma.
Hu ZY; Yuan SX; Yang Y; Zhou WP; Jiang H
J Exp Clin Cancer Res; 2014 Jul; 33(1):61. PubMed ID: 25060425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
